

The ELZONRIS Information Card

Keep the attached card in your wallet or purse

It is important that all your healthcare providers know you are being treated with ELZONRIS® (tagraxofusp-erzs). Be sure to show the **ELZONRIS Information Card** to any healthcare provider who is not a part of your cancer treatment team or if you go to the emergency room.

ELZONRIS Information Card

Cancer Diagnosis: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Medication: ELZONRIS® (tagraxofusp-erzs)

This medication may be associated with serious side effects, including Capillary Leak Syndrome (CLS). Symptoms of CLS include changes in serum albumin, rapid weight gain, edema, fluid retention, and hypotension.

Boxed WARNING: CAPILLARY LEAK SYNDROME

- **Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended**

Please see full Prescribing Information, including Boxed WARNING, at ELZONRIS.com/hcp.

Fill out this card

ELZONRIS Information Card

Cancer Diagnosis: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Medication: ELZONRIS® (tagraxofusp-erzs)

This medication may be associated with serious side effects, including Capillary Leak Syndrome (CLS). Symptoms of CLS include changes in serum albumin, rapid weight gain, edema, fluid retention, and hypotension.

Boxed WARNING: CAPILLARY LEAK SYNDROME

- **Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended**

Please see full Prescribing Information, including Boxed WARNING, at ELZONRIS.com/hcp.

Keep this as a spare card

How to use this card

- Peel the **ELZONRIS Information Card** off the page
- Fill out the back of the card with your name, the date you started receiving ELZONRIS, and your prescribing physician's name and phone number
- Immediately put the card in your wallet or purse
- Show this card to any healthcare provider if you go to the emergency room or if you see any other healthcare provider who is not a part of your cancer treatment team
- Ask your cancer treatment team for another card if your card is lost or damaged
- Keep this card in your wallet or purse until your treatment team tells you that you don't need it anymore

Please see Important Safety Information on the reverse side and accompanying full Prescribing Information, including **Boxed WARNING**, for ELZONRIS to learn more.

About ELZONRIS® (tagraxofusp-erzs)

ELZONRIS is a prescription medicine used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years and older.

IMPORTANT SAFETY INFORMATION

ELZONRIS can cause serious side effects, including:

- **Capillary Leak Syndrome (CLS).** ELZONRIS can cause fluid to leak from small blood vessels into your body's tissues. This is called "Capillary Leak Syndrome." CLS can quickly cause you to have symptoms that may become life-threatening or fatal (ie, lead to death). **Get emergency medical help immediately if you develop any of the following symptoms:**
 - fast weight gain
 - swelling of your face, arms, hands, legs, or feet
 - shortness of breath or difficulty breathing
 - low blood pressure (dizziness or lightheadedness, headache, feeling tired, or shortness of breath)

Weigh yourself daily. Your healthcare provider will also check your weight and test your blood before you receive each dose of ELZONRIS and as needed during treatment.

- **Hypersensitivity reactions** may occur with ELZONRIS. Symptoms may include rash, itching (pruritus), wheezing, or swelling in your face, including around your eyes and/or in and around your mouth
- **Liver damage** is usually detected through blood tests. Symptoms may include feeling tired (fatigue), loss of appetite, yellowing of your skin or the whites of your eyes (jaundice), or upper right abdominal pain or discomfort

Your healthcare provider will periodically test your blood while you are on ELZONRIS to check for liver damage. Contact your healthcare provider immediately if you have any of these symptoms.

Getting medical treatment right away may help keep these problems from becoming more serious.

If you have any side effects during treatment with ELZONRIS, your healthcare provider may hold your treatment for a period of time or completely stop your treatment with ELZONRIS.

The most common side effects of ELZONRIS include CLS, nausea, feeling tired (fatigue), fever, swelling in your legs or feet, and weight gain.

These are not all of the possible side effects of ELZONRIS. If any new side effects start or an existing one gets worse, contact your healthcare provider immediately. For more information, talk to your treatment team.

Be sure to tell your treatment team about:

- all of your medical conditions, including if you
 - are pregnant or plan to become pregnant. ELZONRIS may harm your unborn baby
 - If you are a female who can become pregnant, you should use effective birth control during ELZONRIS treatment and for 1 week after the last dose
 - Tell your healthcare provider right away if you become pregnant during treatment with ELZONRIS
 - are breastfeeding or plan to breastfeed. It is not known if ELZONRIS passes into breast milk. You and your healthcare provider should decide if you will receive ELZONRIS or breastfeed. You should not do both
- all of the medicines you take, including prescription medicines, over-the-counter medicines, vitamins, and herbal supplements

You can report any side effects to Stemline Therapeutics, Inc. at 1-877-332-7961 or contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information, including **Boxed WARNING**, for ELZONRIS to learn more.

The risk information provided here is not comprehensive. To learn more, talk about ELZONRIS (tagraxofusp-erzs) with your healthcare provider or pharmacist. The FDA-approved product labeling can be found at www.elzonris.com.

ELZONRIS Information Card

Cancer Diagnosis: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Medication: ELZONRIS® (tagraxofusp-erzs)

This medication may be associated with serious side effects, including Capillary Leak Syndrome (CLS). Symptoms of CLS include changes in serum albumin, rapid weight gain, edema, fluid retention, and hypotension.

Boxed WARNING: CAPILLARY LEAK SYNDROME

- **Capillary Leak Syndrome (CLS) which may be life-threatening or fatal, can occur in patients receiving ELZONRIS. Monitor for signs and symptoms of CLS and take actions as recommended**

Please see full Prescribing Information, including Boxed WARNING, at ELZONRIS.com/hcp.

Patient Name: _____

ELZONRIS Start Date: _____

Prescribing Physician: _____

Physician Phone Number: _____